DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, L.
Right arrow Articles by Crespi, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, L.
Right arrow Articles by Crespi, C. L.

0090-9556/97/2504-0399-0405$02.00/0
DRUG METABOLISM AND DISPOSITION
Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics
Vol. 25, No. 4

Coexpression of Cytochrome P4502A6 and Human NADPH-P450 Oxidoreductase in the Baculovirus System

Liping Chen, Jeroen T. M. Buters, James P. Hardwick, Shingi Tamura, Bruce W. Penman, Frank J. Gonzalez, and Charles L. Crespi

Gentest Corporation (L. C., B. W. P., C. L. C.); National Cancer Institute (J. T. M. B., S. T., F. J. G.), National Institutes of Health; and Northeastern Ohio Universities College of Medicine (J. P. H.)

Heterologous expression using baculovirus vectors has become a popular method for the production of catalytically active cytochrome P450s (CYPs). We have systematically optimized the multiplicity of infection (MOI) for a coinfection approach for the coexpression of CYP2A6 (viral vector designated v2A6) and NADPH-P450 oxidoreductase (OR; viral vector designated vOR) using Sf9 insect cells. A 3000-fold range of MOI was examined in stationary culture and stirred suspension culture. Surprisingly, our results indicate that the best CYP2A6 catalytic activity (850-1300 pmol/min/mg total lysate protein as measured by coumarin 7-hydroxylase activity) was obtained only when using a low MOI of v2A6 (1.5-3 × 10-2) and a vOR of 10- to 20-fold less. This activity was ~7- to 11-fold higher than the best activity obtained when infecting cells with v2A6 alone. At this level of coinfection, the P450 content ranged from 180 to 250 pmol/mg total lysate protein, and the NADPH cytochrome c reductase activity ranged from 350 to 520 nmol/min/mg total lysate protein. Increasing the MOI of both viruses to 50-fold higher resulted in lower overall activity with the optimum (250 pmol/min/mg total lysate protein) being seen earlier postinfection (60 vs. 72 hr). Increasing the MOI of vOR to levels comparable with those of v2A6, decreased coumarin 7-hydroxylase activity 14-fold. These results suggest that the best CYP2A6 catalytic activity depends on properly posttranslationally modified proteins accumulating in a right ratio as a result of primary, secondary, and possibly tertiary infection of both viruses. These results also suggest that high OR expression results in degradation of P450.


Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Protein Eng Des SelHome page
S. G. Bell, C. F. Harford-Cross, and L.-L. Wong
Engineering the CYP101 system for in vivo oxidation of unnatural substrates
Protein Eng. Des. Sel., October 1, 2001; 14(10): 797 - 802.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
D. Schwarz, P. Kisselev, I. Cascorbi, W.-H. Schunck, and I. Roots
Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants
Carcinogenesis, March 1, 2001; 22(3): 453 - 459.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. A. Shultz, P. V. Choudary, and A. R. Buckpitt
Role of Murine Cytochrome P-450 2F2 in Metabolic Activation of Naphthalene and Metabolism of Other Xenobiotics
J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 281 - 288.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.